Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;62(4):614-625.
doi: 10.1016/j.amepre.2021.10.020. Epub 2022 Feb 10.

Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis

Karla I Galaviz  1 , Mary Beth Weber  2 , Kara Suvada BS  2 , Unjali P Gujral  2 , Jingkai Wei  3 , Rozina Merchant  4 , Sahrudh Dharanendra  2 , J Sonya Haw  4 , K M Venkat Narayan  5 , Mohammed K Ali  5
Affiliations

Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis

Karla I Galaviz et al. Am J Prev Med. 2022 Apr.

Abstract

Introduction: Several interventions have been found to be effective for reversing prediabetes in adults. This systematic review and meta-analysis aims to compare the effectiveness of such interventions.

Methods: MEDLINE, Embase, and Cochrane Library databases were searched for articles published between January 1, 2000 and June 27, 2018. RCTs in adults with prediabetes, testing nonsurgical interventions lasting for ≥3 months, and reporting the number of participants achieving normal glucose levels at intervention end were eligible. The pooled risk difference and number needed to treat for achieving normoglycemia were estimated using a random-effects, arm-based network meta-analysis. The strength of the evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation. Data were obtained in 2018 and analyzed in 2019 and 2021.

Results: Of 54 studies included in the systematic review, 47 were meta-analyzed (n=26,460, mean age=53 years, 46% male, 31% White). Studies included 27 arms testing lifestyle modification interventions, 25 testing medications, 5 testing dietary supplements, and 10 testing Chinese medicine. There were 35 control/placebo arms. At a median follow-up of 1.6 years, more participants in the lifestyle modification groups achieved normoglycemia than those in the control (risk difference=0.18, number needed to treat=6). The strength of the evidence was strong for lifestyle modification. Over a median follow-up of 2.7 years, more participants receiving glucagon-like peptide-1 receptor agonists (risk difference=0.47, number needed to treat=2), α-glucosidase inhibitors (risk difference=0.29, number needed to treat=4), and insulin sensitizers (risk difference=0.23, number needed to treat=4) achieved normoglycemia than control. The strength of evidence was moderate for these medications.

Discussion: Although several pharmacological approaches can reverse prediabetes, lifestyle modification provides the strongest evidence of effectiveness and should remain the recommended approach to address this condition.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare during the course of this work. No financial disclosures were reported by the authors of this paper.

Figures

Appendix Figure 1.
Appendix Figure 1.
PRISMA study selection flow chart.
Appendix Figure 2.
Appendix Figure 2.
Risk of bias assessment results.
Appendix Figure 3.
Appendix Figure 3.
Node-split showing risk difference obtained from direct treatment comparisons (i.e., in same study) and from indirect comparisons (i.e., obtained in this meta-analysis).
Figure 1.
Figure 1.
Network structure showing an asymmetrical network. Notes: The size of the bubble represents the number of studies testing a treatment and the thickness of the connecting lines the number of arms testing that comparison. AGI, alpha-glucosidase inhibitors; DPP-4, dipeptidyl peptidase 4 inhibitors; GLP-1, glucagon-like peptide 1 receptor agonists; LSM, lifestyle modification; RAS, renin-angiotensin system.
Figure 2.
Figure 2.
Forest plot showing pooled effects for each treatment against control/placebo. AGI, alpha-glucosidase inhibitors; DPP-4, dipeptidyl peptidase 4 inhibitors; GLP-1, glucagon-like peptide 1 receptor agonists; LSM, lifestyle modification; RAS, renin-angiotensin system; NNT, number needed to treat; RD, risk difference; RR, relative risk.
See this image and copyright information in PMC

Comment in

References

    1. Hostalek U Global epidemiology of prediabetes - present and future perspectives. Clin Res Diabetes Endocrinol. 2019;5:5. 10.1186/s40842-019-0080-0. - DOI - PMC - PubMed
    1. International Diabetes Federation. IDF Diabetes Atlas, 9th Edition. https://www.diabetesatlas.org/en/. Published 2019. Accessed on March 19, 2020.
    1. Yip WCY, Sequeira IR, Plank LD, Poppitt SD. Prevalence of pre-diabetes across ethnicities: a review of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) for classification of dysglycaemia. Nutrients. 2017;9(11):1273. 10.3390/nu9111273. - DOI - PMC - PubMed
    1. Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Prac. 2007;78(3):305–312. 10.1016/j.diabres.2007.05.004. - DOI - PubMed
    1. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004;164(19):2147–2155. 10.1001/archinte.164.19.2147. - DOI - PubMed

REFERENCES FOR THE 54 STUDIES IDENTIFIED IN THE SYSTEMATIC REVIEW

    1. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104–1115. 10.1056/nejmoa1010949. - DOI - PubMed
    1. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33(6):1173–1175. 10.2337/dc09-1203. - DOI - PMC - PubMed
    1. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF. Regression from pre-diabetes to normal glucose regulation in the Diabetes Prevention Program. Diabetes Care. 2009;32(9):1583–1588. 10.2337/dc09-0523. - DOI - PMC - PubMed
    1. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379(9833):2243–2251. 10.1016/s0140-6736(12)60525-x. - DOI - PMC - PubMed
    1. Snehalatha C, Mary S, Selvam S, et al. Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). Diabetes Care. 2009;32(10):1796–1801. 10.2337/dc09-0676. - DOI - PMC - PubMed

Publication types